Dolutegravir for the treatment of adult patients with HIV-1 infection.

about

Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations.

P2860

Q38367106-6F42150B-1166-4B70-8C12-B2194A2394CF

P2860

Dolutegravir for the treatment of adult patients with HIV-1 infection.

Item

http://www.wikidata.org/entity/Q38201520

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Dolutegravir for the treatment of adult patients with HIV-1 infection.

@en

type

Item

label

Dolutegravir for the treatment of adult patients with HIV-1 infection.

@en

prefLabel

Dolutegravir for the treatment of adult patients with HIV-1 infection.

@en

P1476

Dolutegravir for the treatment of adult patients with HIV-1 infection.

@en

P2093

Gary Wu

http://www.w3.org/2001/XMLSchema#string

Nasser Saad

http://www.w3.org/2001/XMLSchema#string

Teena Abraham

http://www.w3.org/2001/XMLSchema#string

P2860

Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics

Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada

Response to the AIDS pandemic--a global health model.

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.

Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.

Integrase inhibitors: a novel class of antiretroviral agents.

P304

535-544

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14787210.2014.907525

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24694091

http://www.w3.org/2001/XMLSchema#string

Dolutegravir for the treatment of adult patients with HIV-1 infection.

about

P2860

P2860

Dolutegravir for the treatment of adult patients with HIV-1 infection.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698